You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

60 Results
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ruxolitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
*/
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Rituxan® SC
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Cyramza®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2023
Drug
Other Name(s): Tomudex®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2024
Drug
Other Name(s): Jakavi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Kisqali™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Sep 2025
Drug
Other Name(s): Stivarga®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2023
Drug
Other Name(s): Orgovyx®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2025
Drug
Other Name(s): Istodax®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2023

Pages